Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in ...

Daiichi Sankyo notes however that Delytact is the first oncolytic virus ever approved for a primary brain cancer in any region of the world, and is also its fourth cancer product approval in the ...